Loeser, Heike ORCID: 0000-0003-4555-1327, Kraemer, Max, Gebauer, Florian, Bruns, Christiane, Schroder, Wolfgang, Zander, Thomas, Alakus, Hakan, Hoelscher, Arnulf, Buettner, Reinhard, Lohneis, Philipp and Quaas, Alexander (2020). Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma. J Immunol. Res., 2020. LONDON: HINDAWI LTD. ISSN 2314-7156
Full text not available from this repository.Abstract
Background. Indoleamine 2,3-dioxygenase (IDO) is an interferon-inducible immune checkpoint expressed on tumor-infiltrating lymphocytes (TILs). IDO is known as a poor prognostic marker in esophageal squamous cell cancer, while a positive effect was shown for breast cancer. A comprehensive analysis of IDO expression in a well-defined cohort of esophageal adenocarcinoma (EAC) is missing.Methods. We analyzed 551 patients with EAC using single-protein and multiplex immunohistochemistry as well as mRNA in situ technology for the expression and distribution of IDO on subtypes of TILs (INF-gamma mRNA and CD4- and CD8-positive T lymphocytes).Results. IDO expression on TILs was seen in up to 59.6% of tumors, and expression on tumor cells was seen in 9.2%. We found a strong positive correlation of IDO-positive TILs, CD3-positive T lymphocytes, and INF-gamma mRNA-producing TILs in the tumor microenvironment of EACs showing significantly better overall survival (47.7 vs. 22.7 months,p<0.001) with emphasis on early tumor stages (pT1/2: 142.1 vs. 37.1 months,p<0.001). In multivariate analysis, IDO is identified as an independent prognostic marker.Conclusions. Our study emphasizes the importance of immunomodulation in EAC marking IDO as a potential biomarker. Beyond this, IDO might indicate a subgroup of EAC with an explicit survival benefit.
Item Type: | Journal Article | ||||||||||||||||||||||||||||||||||||||||||||||||
Creators: |
|
||||||||||||||||||||||||||||||||||||||||||||||||
URN: | urn:nbn:de:hbz:38-318563 | ||||||||||||||||||||||||||||||||||||||||||||||||
DOI: | 10.1155/2020/2862647 | ||||||||||||||||||||||||||||||||||||||||||||||||
Journal or Publication Title: | J Immunol. Res. | ||||||||||||||||||||||||||||||||||||||||||||||||
Volume: | 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||
Date: | 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||
Publisher: | HINDAWI LTD | ||||||||||||||||||||||||||||||||||||||||||||||||
Place of Publication: | LONDON | ||||||||||||||||||||||||||||||||||||||||||||||||
ISSN: | 2314-7156 | ||||||||||||||||||||||||||||||||||||||||||||||||
Language: | English | ||||||||||||||||||||||||||||||||||||||||||||||||
Faculty: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||
Divisions: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||
Subjects: | no entry | ||||||||||||||||||||||||||||||||||||||||||||||||
Uncontrolled Keywords: |
|
||||||||||||||||||||||||||||||||||||||||||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/31856 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
View Item |